Profile data is unavailable for this security.
About the company
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
- Revenue in USD (TTM)0.00
- Net income in USD-7.35m
- Incorporated2018
- Employees8.00
- LocationShuttle Pharmaceuticals Holdings Inc401 Professional Drive, Suite 260GAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 403-4212
- Fax+1 (845) 818-3588
- Websitehttps://shuttlepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hoth Therapeutics Inc | 0.00 | -7.70m | 4.25m | 2.00 | -- | 0.4891 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
Evoke Pharma Inc | 6.11m | -7.13m | 4.64m | 4.00 | -- | 1.33 | -- | 0.7604 | -1.83 | -1.83 | 1.28 | 0.4068 | 0.5429 | 0.5113 | 5.71 | 1,526,428.00 | -63.39 | -100.48 | -76.67 | -151.10 | 96.01 | -- | -116.76 | -480.52 | 5.35 | -19.25 | 0.5884 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
Titan Pharmaceuticals Inc | 87.00k | -4.95m | 4.71m | 4.00 | -- | 0.7736 | -- | 54.12 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
Processa Pharmaceuticals Inc | 0.00 | -9.83m | 4.94m | 13.00 | -- | 0.5562 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
Hanyuan Biotech International Inc | 10.65m | 3.14m | 5.28m | -- | 0.0294 | 0.0064 | 1.45 | 0.4957 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
Stemtech Corp | 4.64m | -4.08m | 5.63m | 45.00 | -- | -- | -- | 1.21 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
SYBLEU Inc | 11.70k | -307.88k | 5.92m | -- | -- | -- | -- | 505.72 | -0.0293 | -0.0293 | 0.0011 | -0.0367 | 0.0641 | -- | -- | -- | -168.63 | -- | -- | -- | -- | -- | -2,631.45 | -- | -- | -8.48 | 4.96 | -- | 0.00 | -- | 26.51 | -- | -- | -- |
Integrated BioPharma, Inc. | 50.57m | -116.00k | 6.02m | 141.00 | -- | 0.3183 | 28.40 | 0.119 | -0.0041 | -0.0041 | 1.67 | 0.6283 | 1.88 | 4.45 | 10.76 | 358,617.00 | -0.431 | 15.51 | -0.5698 | 27.94 | 7.09 | 12.09 | -0.2294 | 6.44 | 1.02 | -9.00 | 0.001 | -- | -9.91 | 3.00 | -101.35 | -- | -14.03 | -- |
GT Biopharma Inc | 0.00 | -9.64m | 6.21m | 2.00 | -- | 0.7487 | -- | -- | -7.04 | -7.04 | 0.00 | 3.85 | 0.00 | -- | -- | 0.00 | -64.24 | -205.36 | -90.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
Sunshine Biopharma Inc | 26.74m | -4.09m | 6.50m | 44.00 | -- | 0.0138 | -- | 0.243 | -13.35 | -13.35 | 76.96 | 24.96 | 0.9081 | 3.13 | 11.58 | 607,722.50 | -13.88 | -101.52 | -17.99 | -137.04 | 33.15 | 35.47 | -15.29 | -165.33 | 3.23 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.35m | 6.53m | 8.00 | -- | 2.37 | -- | -- | -0.4739 | -0.4739 | 0.00 | 0.1642 | 0.00 | -- | -- | 0.00 | -96.75 | -- | -119.37 | -- | -- | -- | -- | -- | -- | -5.28 | 0.2542 | -- | -- | -- | -112.71 | -- | -- | -- |
Sonoma Pharmaceuticals Inc | 12.74m | -4.84m | 6.84m | 172.00 | -- | 0.9153 | -- | 0.5371 | -0.7237 | -0.7237 | 1.40 | 0.3932 | 0.8224 | 2.87 | 4.66 | 74,040.70 | -31.22 | -29.36 | -41.09 | -40.65 | 37.26 | 38.00 | -37.97 | -30.93 | 2.64 | -- | 0.05 | -- | -4.05 | -7.66 | 6.13 | -- | -29.84 | -- |
Cannapharmarx Inc | 25.84k | -6.61m | 7.29m | 21.00 | -- | -- | -- | 282.02 | -0.0205 | -0.0205 | 0.00008 | -0.0425 | 0.0031 | -- | 0.4503 | 1,230.48 | -79.52 | -131.06 | -- | -- | -1,692.76 | -- | -25,598.30 | -- | 0.0033 | -0.1306 | -- | -- | -- | -- | 143.24 | -- | -- | -- |
Healthy Extracts Inc | 2.56m | -2.76m | 7.41m | -- | -- | 48.86 | -- | 2.89 | -0.9512 | -0.9512 | 0.8819 | 0.0512 | 0.9428 | 0.5035 | 32.10 | -- | -101.47 | -53.78 | -375.65 | -146.65 | 68.46 | 45.68 | -107.63 | -87.53 | 0.1293 | -2.22 | 0.879 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 7.41m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Tonix Pharmaceuticals Holding Corp | 10.25m | -98.59m | 7.87m | 103.00 | -- | 0.017 | -- | 0.7675 | -177.41 | -177.41 | 9.46 | 46.94 | 0.0652 | -- | -- | 99,514.56 | -62.71 | -59.46 | -70.20 | -65.92 | 37.55 | -- | -961.87 | -5,126.73 | 0.8666 | -- | 0.0767 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
Holder | Shares | % Held |
---|---|---|
Geode Capital Management LLCas of 31 Mar 2024 | 36.96k | 0.22% |
Renaissance Technologies LLCas of 31 Mar 2024 | 16.50k | 0.10% |
Virtu Americas LLCas of 31 Mar 2024 | 10.48k | 0.06% |
UBS Securities LLCas of 31 Mar 2024 | 1.12k | 0.01% |
Desjardins Securities, Inc.as of 31 Mar 2024 | 500.00 | 0.00% |
Tower Research Capital LLCas of 31 Mar 2024 | 251.00 | 0.00% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 54.00 | 0.00% |
StoneX Group, Inc. (Investment Management)as of 31 Mar 2024 | 0.00 | 0.00% |